Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

EMA Safety Panel Recommends Withdrawing Esmya Authorizations

Executive Summary

Marketing authorizations for Gedeon Richter’s Esmya and generic versions are certain to be revoked, after a review by the European Medicines Agency’s safety committee concluded that the uterine fibroids drug “can cause liver injury, including the need for liver transplantation.”

You may also be interested in...



Gedeon Richter Gearing Up For Denosumab And Tocilizumab

Hungary’s Gedeon Richter is continuing efforts to bring multiple biosimilars to market, while reaping the benefits of the biosimilar to Eli Lilly’s Forsteo (teriparatide) in the EU and Japan. Management discussed Richter’s achievements on the company’s first-half earnings call, while also commenting on how markets have reacted to the COVID-19 pandemic.

Ulipristal Suspended In EU Pending Further Review

Gedeon Richter's Esmya should not be prescribed to women while the European Medicines Agency again reviews the risk of serious hepatic injury. 

Alvogen Targets Esmya With First European Rival

Alvogen has gained European approvals for a rival to Gedeon Richter’s Esmya through the decentralized procedure.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

ID001014

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel